The lawsuit claims that three major healthcare companies were pushing up the price of insulin by 1,200 percent.

Regulators published their most detailed findings yet on how some of the nation’s largest companies profited from "excess" ...

The Federal Trade Commision (FTC) found prescription benefits managers like UnitedHealth's OptumRX have gained $7.3B from ...

In the debate over the high cost of prescription drugs, pharmacy benefit managers are hotly contested. PBMs, the middlemen in ...

Agency commissioners voted unanimously on Tuesday to publish the report, which makes similar allegations against the ...

The Federal Trade Commission voted unanimously to release additional findings from its yearslong probe into CVS Caremark, ...

Agency commissioners voted unanimously on Tuesday to publish the report, which makes a similar attack on the drug middlemen ...

The pressure against pharmacy benefit managers (PBMs) continues to build. On Tuesday, the Federal Trade Commission released ...

The FTC report found that from 2017 to 2022, three PBMs—UnitedHealth Group's Optum, CVS Health's CVS Caremark and Cigna's ...

The Federal Trade Commission (FTC) on Tuesday released its second interim report on pharmacy benefit managers (PBM), saying ...

The new document focuses on the influence of PBMs over the market for specialty generic drugs for illnesses like cancer, ...

Pharmacy benefit managers, which serve as the middlemen between drug makers, insurers and pharmacies, reaped $7.3 billion in ...